Edit

Cernostics

http://www.cernostics.com/

Last activity: 22.10.2021

Active

Categories: AnalyticsArtificial IntelligenceClinicDiagnosticsHealthTechInformationITLearnPlatformTechnology

Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis.

Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple interacting cell types.

Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform [www.cernostics.com] and how it will change the future of cancer diagnostics.

Followers

1.35K

Mentions

Location: United States, Pennsylvania, Pittsburgh

Employees: 11-50

Total raised: $9.06M

Investors 1

Date	Name	Website
-	Illumina V...	illuminaVe...

Funding Rounds 5

Date	Series	Amount	Investors
22.03.2018	-	$2.5M	-
06.09.2016	-	$5M	-
04.12.2013	Series B	$1.4M	-
09.08.2012	-	$100K	-
08.03.2012	-	$55K	-

Mentions in press and media 22

Date	Title	Description
22.10.2021	Biotech firm Cernostics is taken public via acquisition, with capital to expand its team in Pittsburgh	As momentum builds for Pittsburgh life sciences, a new acquisition will take a local biotech company public. Earlier this week, Castle Biosciences announced a $30 million acquisition of Harmar-based Cernostics — a biotech firm that uses art...
11.08.2020	Is Pittsburgh an emerging hub for life sciences tech?	Stephanie Kladakis grew up in Burgettstown, half an hour outside of Pittsburgh. But she assumed she’d have to pursue her career elsewhere. She moved to Boston for college, and eventually her career in biotechnology. But then she attended a ...
22.03.2018	Term Sheet — Thursday, March 22	THE VC WAR CHEST Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop Sequoia Capital is raising as much as $12 billion between its global growth fund and other venture capital and gr...
22.03.2018	Cernostics Raises $2.5M for Next Generation Cancer Diagnostics	Cernostics, a Pittsburgh, PA-based diagnostics company focused on delivering better cancer diagnosis and prognosis through a unique approach to tissue analysis has raised $2.5 million in Series A funding led by Illumina Ventures. With the r...
21.03.2018	Cernostics Raises $2.5 Million in Series A1 Financing	Cernostics, a privately-held company focused on delivering next-generation cancer diagnostics and prognostics, announced today that it has raised $2.5 million in Series A1 financing, led by Illumina Ventures. With this capital investment, C...
21.03.2018	Cernostics Raises $2.5M in Series A1 Financing	Cernostics, a Pittsburgh, PA-based company focused on delivering next-generation cancer diagnostics and prognostics, raised $2.5m in Series A1 financing. The round – which has brought total funding to $13m – was led by Illumina Ventures. Th...
06.09.2016	UPMC backs cancer diagnostics startup Cernostics	This recent infusion of cash will help Pittsburgh-based Cernostics build out the sales and marketing of a test that identifies patients at risk of developing esophageal cancer — before they develop cancer. But the technology, known as Tissu...
06.09.2016	Backed by UPMC, Cancer Diagnostics Startup Cernostics Lands $5M	Cernostics, a Pittsburgh, PA-based cancer diagnostics startup has raised $5 million in funding led by UPMC Enterprises, UPMC’s venture capital arm with participation from Novitas Capital. The company plans to utilize the funding to accelera...
31.08.2016	Cernostics Raises $5M Round from Novitas Capital	As part of its wide-ranging efforts to better target treatments to patients while reducing unnecessary tests and procedures, UPMC announced today that it is investing in and partnering with Cernostics, an oncology diagnostics company whose ...
31.08.2016	Cernostics Raises $5M in Funding	Cernostics, a Pittsburgh and Bethlehem, Pennsylvania-based cancer diagnostics company, raised $5m in funding. The round was led by UPMC Enterprises with participation from Novitas Capital. The company intends to use the funds to grow and ac...
25.03.2014	Diagnostic developer with faster, more accurate esophageal cancer test nets follow-on funding	Tissue Cypher Technology is a molecular test that simultaneously evaluates multiple cells and processes in a single biopsy, according to a statement from Ben Franklin. It’s designed to replace the current process, which is largely manual an...
04.12.2013	Cernostics Raises $1.4M in Series B Funding	Cernostics, a Pittsburgh, PA-based diagnostics company, raised $1.4m in Series B funding. Backers included Novitas Capital, Geisinger Health System and the Pittsburgh Life Sciences Greenhouse. The company intends to use the funds to acceler...
01.08.2013	Diagnostic to predict risk of esophageal cancer raises $1.4 million	Barrett’s esophagus is a condition that can develop as a result of severe gastroesophageal reflux disease or heartburn. Cells in the lower esophagus become damaged, frequently from repeated exposure to stomach acid. Esophageal cancer has on...
17.08.2012	Molecular diagnostics to improve esophageal cancer detection raising $500K	Esophageal cancer has one of the highest mortality rates among cancers, and 13,000 new cases are diagnosed in the United States each year. Risk stratification is difficult for clinicians. Cernostics will continue to develop this molecular d...
09.08.2012	Cernostics Receives $100K Loan from Ben Franklin Technology Partners of Northeastern Pennsylvania	Cernostics, Inc., a Danville, PA-based life science company developing new molecular diagnostic tests, has received a $100k loan from the Ben Franklin Technology Partners of Northeastern Pennsylvania. Led by Mike Hoerres, CEO, and Rebecca C...
09.03.2012	Esophageal cancer risk test developer gets new funding	The Danville, Pennsylvania company said the reason why its test is significant is that current endoscopic tests may fail to detect dysplasia. According to the company, half of the patients first diagnosed with esophageal cancer were negativ...
08.03.2012	Cernostics Receives $55K in Funding from the BFTP/NEP	Cernostics, Inc., a Danville, PA-based life science company developing new molecular diagnostic tests for the fight against cancer, received $55k in funding from the Ben Franklin Technology Partners of Northeastern Pennsylvania (BFTP/NEP). ...
-	Diagnostic developer with faster, more accurate esophageal cancer test nets follow-on funding	Esophageal cancer is one of the fastest growing cancers in western countries and has one of the highest mortality rates among cancers. About 17,990 new cases are diagnosed in the United States each year, according to data from the American ...
-	Esophageal cancer risk test developer gets new funding	A molecular diagnostic testing company has received $55,000 from a Pennsylvania economic development agency to develop a test to determine a patient’s risk for esophageal cancer if they have Barrett’s esophagus. The company is collaborating...
-	UPMC backs cancer diagnostics startup Cernostics	The molecular technology being developed to spot cancer may be less iconic than the old image of pathologists bent over a microscope looking at tiny cells trapped between glass slides. But algorithms and cells have spurred a market teeming ...
-	Molecular diagnostics to improve esophageal cancer detection raising $500K	A molecular diagnostics company developing a test to predict the likelihood that people with Barrett’s esophagus have of developing esophageal cancer is raising $500,000, according to a form D filing with the U.S. Securities Exchange Commis...
-	Diagnostic to predict risk of esophageal cancer raises $1.4 million	A molecular diagnostics company is raising fresh capital for a test to predict the likelihood of a precancerous condition becoming esophageal cancer. The idea is that by detecting the condition earlier and more accurately, it could lead to ...

Cernostics

Investors 1

Funding Rounds 5

Mentions in press and media 22

Reviews 0